3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
NET
1
Lymphoid
1
Gastrointestinal
1
Endocrine
1
Conditions
Pancreatic Neoplasms
4
Gastro-enteropancreatic neuroendocrine tumor
3
Liver Neoplasms
2
Carcinoma, Hepatocellular
2
Pituitary Neoplasms
1
Pancreatic Fistula
1
Neuroendocrine Tumors
1
Neuroectodermal Tumors, Primitive
1
Neoplasm Metastasis
1
Nelson Syndrome
1
Lymphoma, Follicular
1
Hypoglycemia
1
Adenocarcinoma
1
ACTH Syndrome, Ectopic
1
Interventions
aflibercept
2
Radiotherapy
2
Gemcitabine
2
Capecitabine
2
pembrolizumab
1
pasireotide
1
motexafin gadolinium
1
fludarabine
1
entinostat
1
Watchful Waiting
1
Topotecan
1
Thalidomide
1
Rituximab
1
Ritonavir
1
Radiation
1
Polymerase Chain Reaction
1
Nicotine
1
Microarray Analysis
1
Leucovorin
1
Ipilimumab
1
Interleukin-2
1
Indinavir
1
Immunoenzyme Techniques
1
Imatinib Mesylate
1
HMPL-013
1
Gene Expression Profiling
1
Fluorouracil
1
Flow Cytometry
1
Fentanyl
1
Drug Therapy
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Lymphoma, Follicular
×
pasireotide
×
Gastrointestinal
×
Clear all
NCT06784752
2026-04-30
NETTER-3
Novartis
Phase 3
Recruiting
240 enrolled